There is currently no agreement if an analysis for a C-MYC, BLC2, and BCL6 rearrangement should be done in every DLBCL, NOS upon diagnosis or should be restricted to cases with GCB phenotype, a high-grade morphology, or C-MYC positivity [12]. The gene discussed is BCL6; the disease is diffuse large B-cell lymphoma.